Comparative Efficacy Of Two Anti-VEGF Drugs In Treating Macular Edema Associated With Retinal Vein Occlusion.

[摘要] This was a retrospective study of forty eyes of forty patients with macular edema associated withRVO who have received three intravitreal injections monthly of RBZ 0.5 mg (n=12) or BCZ 1.25 mg (n=28). Patients were enrolled between period of 15 May 2017 to 14 May 2019. Endpoints wereimprovement in BCVA and decrease in central macular thickness (CMT) from baseline at six months afterinitial injection. Out of forty patients 30 patients were males (83.33%) and 10 patients were females(16.67%). The patients age ranged from 43 yrs to 75 yrs with mean age of 59 ± 6 years. A subgroupanalysis of BRVO and CRVO showed similar visual improvement.The BCVA significantly improved fromlog Mar 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at six months in RBZ group (p< 0.001) and from log Mar0.58 ± 21 at baseline to log Mar 0.29 ± 0.25 at six months in BCZ group (p<0.001). The mean reduction incentral macular thickness at six months was 236 ± 16.4µm in RBZ group (p< 0.001) and 219 ± 16.1µm inBCZ group (p<0.001).The mean numbers of injections of RBZ or BCZwere three.There was significantvisual improvement in both RBZ and BCZ group for the treatment of RVO and produced significantreduction in central macular thickness with similar visual and anatomical outcome.

[学科分类] 工程和技术（综合）

[关键词] Ranibizumab:(RBZ);Bevacizumab:(BCZ);Best Corrected Visual Acuity:(BCVA);Central Macular Thickness(CMT)